Kornimate/medical-research-clean huggingface dataset:
a randomized controlled trial evaluating of prophylactic irradiation in crt for ct1bn0m0 escc

Conditions: Esophageal Squamous Cell Carcinoma

Summary: this study is conducted to investigate whether modified chemoradiotherapy with elective nodal irradiation reduces the locoregional recurrence that cannot be completely resected by salvage endoscopic resection and preserve esophagus without compromising overall survival.


Eligibility criteria:
inclusion criteria: 1. histologically proven squamous cell carcinoma, adenosquamous carcinoma, or basaloid cell carcinoma. 2. all lesions located in the thoracic esophagus. secondary lesions with an absolute indication for endoscopic resection (emr/esd) may not be confined to the thoracic esophagus. 3. clinical n0m0 with cervical to abdominal contrast-enhanced ct. 4. the deepest lesion is diagnosed as ct1b (sm1 / sm2 / sm3) with upper gastrointestinal endoscopy. if it is difficult to differentiate ct1a-mm and ct1b-sm1 clinically, the wall depth is diagnosed as ct1b-sm1. 5. aged 20 years and older. 6. ecog performance status 0 or 1. 7. no previous therapy against esophageal cancer except for complete resection by emr/esd with either pt1a-lpm (pm2) / pt1a-mm (m3) disease or pt1a-mm (m3) disease without vascular infiltration. 8. no history of radiotherapy for the neck, chest, and upper abdomen for any cancers. no chemotherapy or hormone therapy with less than 3 years of disease-free interval for any cancers. 9. major organ function is preserved. 1) wbc\ =1,500/mm3 3) hb\>=10.0 g /dl 4) plt\>=10,000/mm3 5) t-bil\ =95% 9) ccr\>=60 ml/min 10. patients do not have a preference to receive a surgical resection as an initial therapy after receiving explanations. 11. written informed consent is obtained. exclusion criteria: 1. simultaneous or metachronous (within 5 years) double cancers, except for intramucosal tumor curable with local therapy. 2. active infection requiring systemic therapy. 3. fever over 38 degrees celsius 4. female during pregnancy, within 28 days of post parturition, or during lactation. male who wants a partner's pregnancy. 5. psychological disorder, which is difficult to participate in this clinical study. 6. receiving continuous systemic corticosteroid or immunosuppressant treatment. 7. positive for hbs antigen or hiv antigen. 8. diabetes mellitus, which is uncontrollable with continuous use of insulin or hypoglycemic agents. 9. uncontrolled arterial hypertension. 10. history of unstable angina pectoris within three weeks or myocardial infarction within six months before registration. 11. uncontrolled valvular disease, dilated cardiomyopathy, and hypertrophic cardiomyopathy. 12. severe emphysema, interstitial pneumonia or pulmonary fibrosis based on chest ct. 13. with a history of cerebrovascular disorder within 6 months. 14. drug allergy for iodic drugs.

Keywords: esophageal squamous cell carcinoma chemoradiotherapy radiation field
urdu version of menopause-specific quality of life scale

Conditions: Menopause

Summary: menopause is accompanied by a spectrum of symptoms that are frequently related to hormonal changes. menopause and its symptoms frequently have an impact on postmenopausal women's quality of life. there is a need for culturally adapted screening tool to aid healthcare professionals or clinicians to screen the symptoms of menopausal women, so the aim of this study is to translate the menopause specific quality of life (menqol) into urdu and to find the reliability and validity of the translated version menopause specific quality of life in menopausal women.

menopause is accompanied by a variety of physiological changes and symptoms, including hot flashes, nightly sweating, anxiety, headaches, vaginal dryness, lethargy, irritability, and sleep disturbance. menopause and its symptoms frequently have an impact on postmenopausal women's quality of life, a metric that is influenced by a variety of societal and personal circumstances. the menopause-specific quality of life questionnaire(menqol) evaluates the prevalence and severity of bothersome physical and psychological concerns that women could experience during the menopausal transition. as cross-border and cross-cultural studies continue to increase, there is a greater need for linguistic validation of tools in various societies. until now no translation or adaptation of the menqol questionnaire has been made for the population with different languages in pakistan. there is a need for culturally adapted screening tools to aid healthcare professionals or clinicians to screen the symptoms of menopausal women in the pakistani population. as the urdu language is pakistan's national language so commonly used all over pakistan, so it is required to translate and culturally adapt the menqol scale into urdu language for the pakistani population.

Eligibility criteria:
inclusion criteria: * natural menopause * females who are able to speak and read urdu * volunteer to participate in the study exclusion criteria: * mental in capacity to complete a self-administered questionnaire * communication problem * taking treatment for menopausal symptoms * history of hysterectomy or ovariectomy * any systemic chronic diseases affecting quality of life
follow-up measurement of brain pde10a enzyme levels in huntington´s disease gene expansion carriers

Conditions: Huntington's Disease

Summary: the aim of this study is to measure longitudinally the availability of the pde10a enzyme in hdgecs using the radioligand \[18f\]mni-659. the study will be a follow-up, examining hdgecs from the chdiki1201/pet-hd-pde10a (nct02061722) study from 18 to 28 months after the initial pet measurement.

the hdgecs will perform 2 study visits: visit 1 (screening) and visit 2 (pet analysis utilizing the radioligand \[18f\]mni-659). there will also be 2 telephone follow ups; one after visit 1 (telephone follow-up after screening) and one after visit 2, (telephone follow-up after pet). study visits and telephone follow-ups will take place during a maximum of 97 days.

Eligibility criteria:
inclusion criteria: * have participated in and completed study chdiki1201/pet-hd-pde10a and are capable of providing informed consent or have a legal representative authorized to give consent on their behalf. * otherwise healthy according to medical history, no co-morbidity of psychotic disorders, physical examination, vital signs and laboratory assessments * willing to travel to stockholm (with a companion if requested) for pet examinations * suitable physically and psychologically to travel to stockholm and undergo pet examinations, as judged by the recruiting investigator with attention given to symptoms of chorea and anxiety * willing to comply with the use of adequate contraceptive measures exclusion criteria: * any disease, condition or concomitant medications that significantly compromises the function of the body systems and that, in the opinion of the investigator might interfere with the conduct of the study or the interpretation * regular use of any medication prohibited by this protocol (selective or non-selective pde inhibitors), with the exception for erectile dysfunction medication, which may be temporarily discontinued prior to the pet measurement * history of anaphylactoid or anaphylactic reactions to any allergen including drugs and contrast media * history of other neurological condition (including brain surgery, intracranial hematoma, stroke/cerebrovascular disorders, epilepsy), co-morbidity of psychiatric disorders * clinically relevant findings in hematological, biochemical testing or 12-lead ecg as determined by the evaluating physician * female subjects who are breast-feeding or have a positive pregnancy test at screening or at visit 2
new therapeutic system of ruptured intracranial aneurysms based on big data from chinese population

Conditions: Subarachnoid Hemorrhage, Aneurysmal

Summary: this study aims at clarifying the current situation of emergency treatment of aneurysmal subarachnoid hemorrhage (sah) in china, and analyzing the safety and efficacy of the treatment strategy between interventional treatment and open surgery, so as to improve the diagnosis and treatment of aneurysmal sah.


Eligibility criteria:
inclusion criteria: * patients presented with subarachnoid hemorrhage on ct or lumbar puncture. * the intracranial hemorrhage was caused by rupture of aneurysm and was confirmed on cta、mra or dsa. * patients willing to participate in this clinical trial and attach to regular follow up. exclusion criteria: * intracranial aneurysm correlating to avm. * dissection, false, traumatic and infectious aneurysms. * the rupture of the aneurysm can not be confirmed on cta、mra or dsa. * patients unwilling to participate in this clinical trial and attach to regular follow up.

Keywords: treatment strategy
a thorough qtc evaluation of the effect of semaglutide on cardiac repolarisation in healthy subjects

Conditions: Diabetes; Healthy

Summary: this trial is conducted in europe. the aim of the trial is to evaluate the effect of semaglutide on cardiac repolarisation in healthy subjects.


Eligibility criteria:
inclusion criteria: * bmi (body mass index): 20-30 kg/m\^2 * body weight: 60-110 kg * normal ecg (electrocardiogram) exclusion criteria: * female who is pregnant, breast-feeding or intends to become pregnant or is of child-bearing potential and not using an adequate contraceptive method. women of child-bearing potential must use an effective method of birth control for the duration of the trial and for 5 weeks following the last dose of semaglutide. only highly effective methods of birth control are accepted (i.e. one that results in less than 1% per year failure rate when used consistently and correctly such as implants, injectables, combined oral contraceptives, some intrauterine devices), or sexual abstinence or vasectomised partner * any clinically significant disease history, in the opinion of the investigator, or systemic or organ * history of seizures, epilepsy, syncope, cardiac arrest, cardiac arrhythmia or torsades de pointes, a-v (atrioventricular) block or structural heart disease * family history of long qt (interval in the ecg: from the start of the qrs complex to the end) syndrome (either objectively diagnosed or suggested by sudden death due to cardiac causes before the age of 50 of a 1st degree relative) * family history of sudden cardiac death before the age of 50 of a 1st degree relative * use of prescription or non-prescription systemic or topical medicinal products (except routine vitamins, acetylsalicylic acid, paracetamol and contraceptives) within 3 weeks (or within 5 halflives of the medicinal product, whichever is longest) prior to the first dosing of semaglutide * smoking, drug or alcohol abuse
reducing sedentary time in fibromyalgia patients

Conditions: Fibromyalgia; Veterans

Summary: this study evaluates the feasibility of a behavioral intervention designed to replace sedentary behavior with light physical activity in veterans with fibromyalgia. the study will also evaluate the acceptability of the intervention among veterans and intervention effects on pain and physical function.

recent research suggests that individuals with fibromyalgia (fm) who spend more time in sedentary behavior and less time in light physical activity experience greater clinical pain and overall impact of fm, irrespective of time spent in moderate to vigorous physical activity. to date, no studies have investigated the potential impact of reducing sedentary behavior on key clinical and physical function outcomes in fm. the overall objective of the pilot project is to design and evaluate the feasibility of an 8-week behavioral intervention designed to replace sedentary behavior with light physical activity in veterans with fm. mixed (quantitative and qualitative) methods will be used to evaluate the behavioral intervention, which is based on constructs from social cognitive and self-regulatory theories that consistently identify important drivers of behavior change as: education, goal-setting, self-monitoring and behavioral prompts to move via an activity tracker and phone app, and feedback on behavior via weekly meetings.

Eligibility criteria:
inclusion criteria: veterans will be eligible if they have: * 2010 american college of rheumatology (acr) diagnostic criteria for fibromyalgia: widespread pain index (wpi) greater than 7 and symptom severity scale (ss) greater than 5 or wpi 3-6 and ss greater than 9. * symptoms have been present at a similar level for at least 3 months * the subject does not have a disorder that would otherwise explain the pain * moderate pain severity (pain severity score greater than 5) * no changes in fibromyalgia medications for last 4 weeks * self-reporting at least 8 hours per day sitting on 5 or more days per week * having access to either an android or iphone smart phone with access to internet exclusion criteria: * significant cardiovascular disease * chronic obstructive pulmonary disease (copd) or asthma needing home oxygen * stroke or transient ischemic attack (tia) in last 6 months * cancer (other than skin cancer) and receiving treatment for it * active psychosis * active suicidal ideation * moderate to severe cognitive impairment * engaging in more than 30 minutes of moderate to vigorous physical activity 3 or more days per week * currently using an app or activity tracker to track physical activity * enrolled in another research study related to pain or exercise
randomized controlled trial (rct) umbilical hernia repair (uhr) absorbable vs non-absorbable synthetic mesh

Conditions: Umbilical Hernia

Summary: the goal of this study is to see which of two types of mesh is better for fixing an umbilical hernia. one type of mesh is an absorbable synthetic mesh, which goes away on its own in the body, and the other type of mesh is a non-absorbable mesh, which stays in the body forever. the researchers will check if the hernia comes back, how it affects the patient's quality of life, and if there are any problems after the surgery during a three-year period.

the goal of this study is to compare the use of absorbable synthetic (as) mesh versus non-absorbable mesh (nas) mesh to determine the 3-year recurrence, quality of life (qol) and postoperative complications in umbilical hernia repair. patients will be randomized into one of two arms to receive an absorbable (enform) mesh or non-absorbable (marlex) mesh. patients will undergo an umbilical hernia repair with the mesh assigned to their randomization cohort. the hernia recurrence, quality of life and postoperative outcomes to determine if the two meshes are non-inferior.

Eligibility criteria:
inclusion criteria: * age 18 years and older * primary umbilical hernia repair (uhr) \[as defined by european hernia society (ehs) guidelines primary midline abdominal wall defect from 3 cm above to 3 cm below the umbilicus\] * undergoing elective laparoscopic or open repair * defect size of 1-4cm2 * centers for disease control and prevention (cdc) class 1 \& 2 wounds exclusion criteria: * none

Keywords: randomized controlled trial (rct) absorbable mesh non-absorbable mesh
response prediction of hyperthermic intraperitoneal chemotherapy in gastro- intestinal cancer

Conditions: Gastric Cancer; Colon Cancer; Peritoneal Carcinomatosis

Summary: patients with gastric or colon cancer with peritoneal carcinomatosis will receive a biopsy of the tumor during their primary curative surgery. the operation is performed according to standard and includes resection of the primary tumor and any metastases and followed by hipec (intraperitoneal hyperthermic chemoperfusion) according to the respective hospital standard. organoid cultures from the biopsies are established in the research laboratory. various chemotherapeutic agents are tested on these tumor organoids in the laboratory and the tumor organoids are analyzed in detail with regard to genetic alterations in order to find alterations that can be addressed, if necessary, by means of targeted drugs against peritoneal carcinomatosis.


Eligibility criteria:
inclusion criteria: * (suspected) synchronous or metachronous peritoneal metastasis of adenocarcinoma of the stomach / gastroesophageal junction (gej) or of the colon or rectum * intraoperative histological confirmation of synchronous or metachronous peritoneal carcinomatosis in gastric carcinoma (incl. gej) or colon carcinoma (incl. rectal carcinoma) * intraoperative peritoneal cancer index (pci) ≤ 15 for gastric carcinoma and ≤ 20 for colon carcinoma. * possibility of surgical resection of peritoneal carcinomatosis (cytoreductive surgery) in curative intention with achievement of a completeness of cytoreduction score (ccs) of 0-1 * no contraindication to surgery * no contraindication against the performance of hipec * expected survival of 6 months at least * ecog ≤ 2 * female and male patients ≥ 18 years of age * patient is able and willing to give written informed consent and comply with the study protocol exclusion criteria: * presence of non-resectable distant metastases * patients with extensive metastasis (e.g., multiple bilobular liver metastases, hepatic and pulmonary metastases, multiple retroperitoneal lymph node metastases; oligometastasis is allowed) * patients with recurrence of peritoneal carcinomatosis (e.g., previous peritonectomy in the course of primary tumor resection) * patients after previous palliative chemotherapy or radiation of the tumor (exception: neoadjuvant and/or adjuvant therapies) * hypersensitivity/allergy to components of the planned intraperitoneal chemotherapy * patients not eligible for surgery/hipec (e.g., heart failure nyha ≥iii, myocardial infarction within the last 3 months before surgery, high-risk cardiac arrhythmias) * secondary malignant disease that occurred \<5 years ago (exception: early stage of a localized tumor with in-sano resection, for example in situ carcinoma of the cervix, adequately treated basal cell carcinoma of the skin) * patients who are housed in a closed facility * pregnant or breastfeeding patients, or patients who plan to become pregnant within 7 months after the end of treatment to become pregnant

Keywords: organoid
pilot rct of efficacy of perineural local anesthetics and steroids for chronic post-traumatic ankle and foot pain

Conditions: CHRONIC POST-TRAUMATIC NEUROPATHIC PAIN IN ANKLE AND FOOT

Summary: injections of local anesthetics (freezing) and steroids are often performed around injured nerves in individuals with nerve injury-related pain. the current standard of medical care is to inject a combination of local anesthetics and steroids around injured nerves, but there is no proof that this is better than injecting only local anesthetic, or even just sterile salt water. there is evidence to believe that injection of local anesthetic (without the steroid) can calm the injured nerve, and provide pain relief from a few days up to a few months. injection of sterile salt water also has the potential to provide pain relief by breaking scar tissue around the nerve, thereby relieving compression. the aim of this study is to compare pain relief and possible adverse effects from these three different treatments for foot and ankle nerve pain relief. all 30 participants will be recruited over 9 months from the altum health clinic at toronto western hospital. 10 participants will be randomly assigned to each treatment. each patient will receive 3 injections over 3 weeks or so. participants will have an in-clinic follow-up at 1 month after the last injection, and a phone follow-up 3 months after the last injection. this is a small-scale study, and information obtained from this study will help in planning and conduct of a larger study with more participants. the larger study will help determine the best possible option for injection in patients with nerve-related injury pain.


Eligibility criteria:
inclusion criteria: 1. pain in foot in neuro-anatomically congruent location following trauma (including surgery) for more than three months 2. physician-reported dn4 scoring confirming neuropathic pain (score \> 3/10) 3. average intensity of pain more than 3/10 on numerical rating score 4. failed trial of appropriate doses of first line medications for neuropathic pain (anticonvulsants and/or antidepressants) for six weeks exclusion criteria: 1. age \< 18 or age ≥ 80 years 2. perineural or intra-articular steroid injections in the last 6 months 3. allergy to local anesthetics and/or steroids 4. ongoing litigation issues related to the patient's pain 5. pregnancy 6. coagulopathy or systemic infection 7. peripheral neuropathy or myopathy, central neuropathic pain (e.g. post-stroke pain) 8. infection in the ankle or foot 9. an unstable medical or psychiatric condition 10. significant catastrophizing as indicated by pain catastrophizing scale (pcs) score equal to or more than 30/52

Keywords: ankle pain foot pain methylprednisolone neuropathic pain
protection of cardiovascular function with crocin in breast cancer patients undergoing radiotherapy and chemotherapy

Conditions: Breast Cancer

Summary: the potential cardiovascular toxicity of tumor treatment and its resulting cardiovascular events have gradually become an important health risk for tumor survivors. prevention and early identification of cardiovascular toxicity has now become one of the bottlenecks in improving the prognosis of cancer patients. compared to conventional echocardiographic indicators, new ultrasound technology based on speckle tracking imaging (sti) has shown superiority in the diagnosis, risk stratification and prognosis evaluation of cardiovascular diseases. crocin, one of the main active components of saffron, has been found protective effect on cardiovascular toxicity in basic studies. this is a randomized, double-blind, placebo-controlled, single-center clinical study to observe the effect of crocin on cardiovascular function caused by breast cancer treatment. one hundred and twenty breast cancer patients planning to undergo radiotherapy or chemotherapy will be included and randomly divided into a crocin group and a placebo group to observe the effect of total saffron tablets on cardiovascular function in patients with early breast cancer radiotherapy and chemotherapy. participants will take crocin or placebo (4 tablets/time, 3 times a day) during each cycle of chemotherapy for 8 days, started on the 1st day before radiotherapy/chemotherapy. follow-up was performed every 3 months after enrollment, and the follow-up period was 6 months. primary study endpoints include the differences between groups in the difference in lvef and gls measured by echocardiography at the end of the experiment compared to baseline. secondary study endpoint include the differences in the incidence rates of serum troponin exceeding the upper limit of normal value and nt-probnp higher than the normal age reference value, the frequency and duration of chest tightness, chest pain and palpitation, the degree of arrhythmia and st-t changes displayed by dynamic electrocardiogram, the other echocardiographic parameters (the e/e', global circumferential strain, global radial strain, 3d-gas, lv torsion, lv rotation/derotation velocity, sdi, rvfws, and indexes of left ventricular diastolic function and right ventricular function) at the end of the experiment compared to baseline between the two groups.


Eligibility criteria:
inclusion criteria: 1. age 25-80 years old, female; 2. patients diagnosed with breast cancer by histopathology; 3. patients who plan to receive adjuvant radiotherapy/chemotherapy or combined adjuvant trastuzumab or pertuzumab targeted therapy; 4. patients who completed at least 6 cycles of treatment after enrollment; exclusion criteria: 1. pregnant or breastfeeding women; 2. patients with poor echocardiographic image quality; 3. persistent atrial fibrillation and severe arrhythmia affect the collection and analysis of ultrasound data; 4. patients who are participating in other clinical studies.

Keywords: breast cancer cancer therapy-related cardiac dysfunction crocin echocardiography speckle tracking technology